Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer Academic Article uri icon

Overview

MeSH Major

  • Antiemetics
  • Cisplatin
  • Indoles
  • Neoplasms
  • Ondansetron
  • Quinolizines
  • Serotonin Antagonists
  • Vomiting

abstract

  • A single IV dose of dolasetron mesylate (1.8 or 2.4 mg/kg) has comparable safety and efficacy to a single 32-mg IV dose of ondansetron in patients receiving cisplatin chemotherapy.

publication date

  • August 23, 1996

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 8708713

Additional Document Info

start page

  • 2242

end page

  • 9

volume

  • 14

number

  • 8